Association of Dietary n3 and n6 Fatty Acids Intake with Hypertension: NHANES 2007–2014

Abstract

In view of the inconsistency of the above results, no relevant studies had been reported among the American population after the 2017 new hypertension diagnostic criteria [10] was released, and there was a lack of studies that performed a dose-response relationship. [...]we conducted this cross-sectional study using new hypertension diagnostic criteria and using data from NHANES 2007–2014 to explore the associations between n3, n6 fatty acids intake and n6:n3 ratio and the risk of hypertension, and to explore the corresponding dose-response relationships. 2. Because linolenic acid includes primarily “alpha-linolenic acid” (n3) and lesser amounts of “gamma-linolenic acid” (n6) [41] and there was not a detailed classification of linolenic acid in NHANES, we categorized linolenic acid into n3 fatty acid. [...]in our analyses, n3 fatty acid contained linolenic acid (18:3), stearidonic acid (18:4), eicosatetraenoic acid (20:5), clupanodonic acid (22:5), and docosahexaenoic acid (22:6), and n6 fatty acid contained linoleic acid (18:2) and arachidonic acid (20:4). [...]n3 fatty acid also could reduce angiotensin-converting enzyme activity [55], further inhibit renin-angiotensin-aldosterone system, and reduce the level of blood pressure. [...]we investigated the dose-response relationship between dietary n3 and n6 fatty acids intake and the risk of hypertension.

1. Introduction

The data from the World Health Organization (WHO) showed that the prevalence of hypertension was approximately 22% globally among adults in 2014, and it was expected to rise to 29.2% in 2025 without intervention [1]. In the past about 20 years, the prevalence of hypertension among U.S adults was about 32% and remained at a high level, and there were no significant changes from 1999 to 2014 [2]. At the same time, the expenditures on the treatment and prevention of hypertension are enormous; as reported, the US spent an estimated $51.2 billion from 2012 to 2013 [3]. Hypertension is one of the most common chronic diseases and a major risk factor for disease burden in the world [4], meanwhile it could increase the risk of stroke, cardiovascular disease, kidney failure, dementia, and Parkinson’s disease and so on [5,6,7,8,9]. In view of the huge disease burden of hypertension, the American College of Cardiology (ACC) and American Heart Association (AHA) adjusted the diagnostic criteria for hypertension to 130/80 mmHg in 2017 [10]. It is essential to pay attention to investigate the modifiable risk factors for hypertension and then take the corresponding measures to prevent and control it.

In recent years, epidemiologic studies were conducted to investigate the association between dietary factors and hypertension, such as fruit and vegetables, whole grain, meat, protein, fiber, copper, zinc, and fatty acids [11,12,13,14,15,16,17,18,19]. Among these dietary factors, some are protective factors, such as fruit and vegetables [11,12,13], whole grains [14], and fiber [15]. There are also some risk factors, such as meat [14], a high-salt diet [14], and so on.

n3 and n6 fatty acids are two important components of polyunsaturated fatty acids, with the first of the double bonds in the cis configuration starting from the third and sixth carbon atom, respectively [20]. Studies found n3 and n6 fatty acids were associated with many diseases, such as cardiovascular diseases [21,22,23,24,25], obesity [26,27], metabolic syndrome [23,27,28,29], and diabetes [30,31,32,33]. Meanwhile, some studies found n3, n6 fatty acids intake could decrease the risk of hypertension [34,35,36] but other studies founded there were no association between n3, n6 fatty acids intake and n6:n3 ratio and the risk of hypertension [37,38,39]. In view of the inconsistency of the above results, no relevant studies had been reported among the American population after the 2017 new hypertension diagnostic criteria [10] was released, and there was a lack of studies that performed a dose-response relationship. Therefore, we conducted this cross-sectional study using new hypertension diagnostic criteria and using data from NHANES 2007–2014 to explore the associations between n3, n6 fatty acids intake and n6:n3 ratio and the risk of hypertension, and to explore the corresponding dose-response relationships.

2. Materials and Methods 2.1. Data Source and Study Population

The purpose of National Health and Nutrition Examination Survey (NHANES) is to assess the health and nutritional status among the US population and NHANES adopted a stratified multistage probabilistic sampling method to select a representative sample of the civilian non-institutionalized US population. This study was approved by the National Center for Health Statistics Research Ethics Review Board and informed consent was obtained from every participant.

Publicly available data from NHANES 2007–2008, 2009–2010, 2011–2012, and 2013–2014 were used in this article. In NHANES 2007–2014, there were a total of 40,617 individuals and our analyses were limited to 24,732 individuals aged 18 years and older. Among them, the individuals without complete blood pressure readings (n = 1888), with unreliable 24 h recall data (n = 3873), and with missing weight data (n = 164) were further excluded. Then, we continued to exclude females who were pregnant or lactating (n = 302) and the individuals whose total energy intake less than 500 or above 5000 kcal/day for females, and less than 500 or above 8000 kcal/day for males (n = 71). In the end, a total of 18,434 participants were included in this cross-sectional study (Figure 1).

2.2. Blood Pressure and Definition of Hypertension

Among participants, their blood pressure was measured using a protocol that follows procedures developed by the American Heart Association [40]. Participants rested quietly in a sitting position for 5 min and then their blood pressure was measured three times using a mercury sphygmomanometer by examiners who were certified through a training program. A fourth reading was measured if required and the means of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were calculated.

Hypertension was defined as SBP ≥ 130 mmHg and/or DBP ≥ 80 mmHg or if the participant reported he/she was currently taking medications for hypertension. Newly diagnosed hypertension was defined as SBP ≥ 130 mmHg and/or DBP ≥80 mmHg and without history of hypertension. Stage 1 hypertension was defined as 130 mmHg ≤ SBP < 140 mmHg and/or 80 mmHg ≤ DBP < 90 mmHg, stage 2 hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg.

2.3. Dietary n3 and n6 Fatty Acids Intake

Dietary n3 and n6 fatty acids intakes were obtained from two 24 h dietary recall interviews. The two interviews were collected in-person in the mobile examination center (MEC) and by telephone 3 to 10 days later, respectively. Because linolenic acid includes primarily “alpha-linolenic acid” (n3) and lesser amounts of “gamma-linolenic acid” (n6) [41] and there was not a detailed classification of linolenic acid in NHANES, we categorized linolenic acid into n3 fatty acid. Thus, in our analyses, n3 fatty acid contained linolenic acid (18:3), stearidonic acid (18:4), eicosatetraenoic acid (20:5), clupanodonic acid (22:5), and docosahexaenoic acid (22:6), and n6 fatty acid contained linoleic acid (18:2) and arachidonic acid (20:4). The average daily dietary n3, n6 fatty acids were calculated according to the U.S. Department of Agriculture’s Dietary Research Food and Nutrition Database for Dietary Studies [42] and were adjusted to the body weight. Dietary n3, n6 fatty acids intake and n6:n3 ratio were divided into tertiles.

2.4. Covariates

The following demographic characteristics were included to control the potential effects of confounding: Age (18–39 years, 40–59 years, 60–79 years, and ≥80 years), gender (Male and Female), race (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, and Other race), educational level (Below high school, High school, and Above high school), annual household income (<$20,000 and ≥$20,000), work activity (Vigorous activity, Moderate activity, and Other), recreational activity (Vigorous activity, Moderate activity, and Other), smoking (Smoking at least 100 cigarettes in life or not), drinking (Having at least 12 alcohol drinks per year or not), diabetes (Yes/No) and total daily energy intake. Diabetes was defined according to self-reported diabetes history and total daily energy intake was obtained from two 24 h dietary recall interviews and two 24 h dietary supplement recall interviews.

2.5. Statistical Analysis

We tested the normality of continuous variables by Kolmogorov-Smirnov normality tests and described normal distributed variables with mean ± standard deviation, non-normal distributed variables with median (interquartile range). We adopted Student’s t-tests to compare the mean levels between the hypertension group and the non-hypertension group if the variable was normally distributed, otherwise, the Mann-Whitney U test was adopted. And we adopted Chi-square tests to compare the percentages of categorical variables between the hypertension group and the non-hypertension group. Dietary n3, n6 fatty acids intakes and n6:n3 ratio were categorized based on tertiles (tertile 1: <33th percentile, tertile 2: ≥3 to 67th percentile, tertile 3: ≥67th percentile), and tertile 1 was the referent category. We conducted binary logistic regression analyses to examine the association of dietary n3, n6 fatty acids intake and n6:n3 ratio with hypertension. Model 1 adjusted for age and gender. Model 2 adjusted for race, educational level, income, recreational activity, work activity, drinking status, smoking status, diabetes, and total energy intake (continuous) additionally. And we performed stratified analysis by gender to assess the association between dietary n3, n6 fatty acids intakes and n6:n3 ratio and the risk of hypertension. We further used restricted cubic spline with 3 knots located at the 5th, 50^th, and 95th percentiles of the exposure distribution to assess dose-response relationship, and the adjusted confounding factors in restricted cubic spline were the same as those adjusted in the logistic regression model 2. Considering that the participants who had a history of hypertension might change their dietary pattern, we further excluded these participants and conducted binary logistic regression analyses to examine the association of dietary n3, n6 fatty acids intake and n6:n3 ratio with newly diagnosed hypertension and conducted multivariate logistic regression to examine the association of dietary n3, n6 fatty acids intake and n6:n3 ratio with stage 1 and stage 2 hypertension. We tested the value of the second zero spline coefficient to calculate the non-linear p value. In order to conduct a nationally representative estimate, analyses in this study were weighted, and the weights took into account the stratified, multistage probability sampling design and survey nonresponse. All statistical analyses were conducted by Stata 12.0 (Stata Corporation, College Station, TX, USA). A two-sided p <0.05 was considered statistically significant.

3. Results

The baseline characteristics of participants by hypertension are shown in Table 1. Finally, a total of 18,434 participants were included in this cross-sectional study, among them, 48.9% were males. The prevalence of hypertension was 48.7%. Compared with participants without hypertension, those with hypertension tended to be older, more likely to be male, obese, and diabetic, had lower educational level and household income, more likely to smoke at least 100 cigarettes in their life, and had less total energy intake. There were no differences between the two groups in marital status and drinking status. Moreover, those with hypertension had less n3, n6 fatty acids intake and a lower n6:n3 ratio.

The weighted odds ratios (ORs) with 95% confidence intervals (Cis) of hypertension based on tertiles of dietary n3, n6 fatty acids intakes and n6:n3 ratio are shown in Table 2. In binary logistic regression analyses, compared with the lowest tertile, the ORs with 95% CIs of hypertension for the highest tertile of n3, n6 fatty acids intake and n6:n3 ratio were 0.62 (0.56–0.69), 0.58 (0.53–0.64) and 0.82 (0.73-0.93), respectively. In model 1, after adjusting for age and gender, n3 and n6 fatty acids intakes were still inversely associated with the risk of hypertension, but a negative association between n6:n3 ratio and the risk of hypertension disappeared. Further adjusted race, educational level, income, recreational activity, work activity, drinking status, smoking status, diabetes, and total energy intake in model 2, the ORs with 95% CIs of hypertension were 0.58 (0.49–0.68), 0.53 (0.45–0.63), and 0.92 (0.80–1.06) for n3, n6 fatty acids intake and n6:n3 ratio, respectively.

The association between n3, n6 fatty acids intakes and n6:n3 ratio and the risk of hypertension in stratified analyses by gender are shown in Table 3. Among males, the ORs with 95% CIs of hypertension were 0.61 (0.48–0.79), and 0.49 (0.38–0.63) in model 2 for n3 and n6 fatty acids intake, respectively. And the negative associations of n3 and n6 fatty acids intakes and the risk of hypertension were also found in females. Among males, the association of n6:n3 ratio and the risk of hypertension was only significant in the unadjusted model, and was not significant in model 1 and model 2. The association of n6:n3 ratio and the risk of hypertension in females were similar to the results in males.

The dose-response relationship between n3, n6 fatty acids intakes and the risk of hypertension are shown in Figure 2; Figure 3, respectively. There was a nonlinear negative and L-shaped association between n3 fatty acid intake and the risk of hypertension (p for nonlinearity <0.001), and there was no further significant reduction in hypertension risk beyond 45 mg/kg/day (OR: 0.36; 95% CI: 0.28–0.47). With an increase of n3 fatty acid intake, there was no significant association in hypertension risk beyond 240 mg/kg/day (OR: 0.26; 95% CI: 0.08–1.01) (Figure 2). There also existed a nonlinear negative and L-shaped association between n6 fatty acid intake and the risk of hypertension (p for nonlinearity <0.05), and the prevalence of hypertension decreased with increasing n6 fatty acid intake and reached a plateau when n6 fatty acid intake above 400 mg/kg/day (OR: 0.27; 95% CI: 0.21–0.36) (Figure 3). The adjusted confounding factors in restricted cubic spline were the same as those adjusted in the logistic regression model 2.

Considering that the participants who had a history of hypertension might change their dietary pattern, we further excluded 6,488 participants who had hypertension history or were taking medications for hypertension. The weighted ORs with 95% CIs of newly diagnosed hypertension, stage 1 and stage 2 hypertension based on tertiles of dietary n3, n6 fatty acids intakes and n6:n3 ratio are shown in Table 4. There were significant negative correlations between n3, n6 fatty acids intakes and the risk of newly diagnosed hypertension. After newly diagnosed hypertension being further divided into stage 1 and stage 2 hypertension, the results did not change significantly and all the results were still stable.

4. Discussion

To our knowledge, this is the first study to explore the associations between n3, n6 fatty acids intakes and n6:n3 ratio and the risk of hypertension among the general American population after the 2017 new hypertension diagnostic criteria was released. Our study indicated that the intakes of n3 and n6 fatty acids were associated decreased risk of hypertension. At the same time, the analyses of different stage hypertension and dose-response relationship also found stable results.

The results of our study were consistent with some previous studies [17,35,36,37]. Levinson et al. [35] found n3 fatty acid intake could reduce the risk of hypertension, and the study conducted by Knapp et al. [36] also found this negative association. Meanwhile, our study also indicated n6 fatty acid intake could reduce the risk of hypertension, and the study conducted by Nakamura et al. [17] also indicated this negative association. The association between n6:n3 ratio and the risk of hypertension was not significant in our study, and Mirmiran et al. [37] also found this not significant association. Besides, some randomized controlled studies [43,44] indicated n3 fatty acid intake could reduce the level of blood pressure and study conducted by Skilton et al. [45] also found n3 fatty acid intake could reduce blood pressure. In contrast, Djousse et al. [39] found not statistically significant association between n6 fatty acid intake and the risk of hypertension. Mirmiran et al. [37] found there were no associations between n3, n6 fatty acids intake and the risk of hypertension among the Iranian population. Wang et al. [38] also found that these associations between n3, n6 fatty acids intake and the risk of hypertension among US women were not statistically significant.

N3 and N6 fatty acids belong to polyunsaturated fatty acids. Polyunsaturated fatty acids have the following physiological functions: (1) Esterification of cholesterol, reduce blood cholesterol and triglycerides; (2) reduce platelet aggregation, reduce thrombosis; (3) reduce blood viscosity, improve blood microcirculation and so on. At the same time, eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), the two main n3 fatty acids, have multiple effects, such as improving arterial compliance [46], antiplatelet [47], anti-inflammatory, and reducing oxidative stress [48]. However, the mechanisms between n3, n6 fatty acid intake and the decreased hypertension risk are not fully understood, but several possible mechanisms have been suggested. First, n3 fatty acid could influence the synthesis of arachidonic acid and eicosanoids, thus producing an anti-inflammatory effect [49,50], and we all know inflammatory effects play an important role in the occurrence and development of hypertension. The anti-inflammatory effect could also explain the mechanism between n3 fatty acid and the decreased hypertension risk [51,52]. Second, n3 fatty acid could enhance endothelial vasodilator function [53], reduce reactivity of resistant vessel vascular smooth muscle [54], and increase vascular compliance [46]. Third, n3 fatty acid also could reduce angiotensin-converting enzyme activity [55], further inhibit renin-angiotensin-aldosterone system, and reduce the level of blood pressure. Fourth, in the molecular aspect, n3 and n6 fatty acids have the ability to regulate and they can act as signal molecules on peroxisome proliferator-activated receptors (PPARs), which are known to regulate several metabolic processes, including lipid and glucose metabolism, adipogenesis, inflammatory responses, or oxidative stress [56]. In addition, antioxidation [57], inhibition of thromboxane production, and reduction of plasma homocysteine level [58] could also be used to explain the mechanisms between n3, n6 fatty acid intake and the decreased hypertension risk.

There are several advantages in our study. First, we used 2017 new hypertension diagnostic criteria and conducted this cross-sectional study among the general American population. Second, we investigated the dose-response relationship between dietary n3 and n6 fatty acids intake and the risk of hypertension. Third, considering that the participants who had hypertension history might change their dietary pattern, we further excluded participants who had hypertension history or were taking medications for hypertension, and all results were still statistically significant. Fourth, the large sample size improved the statistical power and reliability of the results.

However, there were also several limitations in our study. First, our study is a cross-sectional study, and it is difficult for us to determine causality. Second, we try to control the confounding factors as much as possible, but we cannot control the confounding factors completely. Third, there was not a detailed classification of linolenic acid in NHANES and we categorized linolenic acid as a n3 fatty acid, this might lead to the results not being very precise. Fourth, the dietary data were from two 24 h dietary recall interviews, this dietary survey method is often imprecise because of conscious or unconscious mis-recordings and under-reporting [59] and there might be ineluctable recall bias. In addition, we could not obtain the intake of n3 fatty acid and n6 fatty acid from dietary supplements, which was an important source of n3 fatty acid and n6 fatty acid.

5. Conclusions

In conclusion, our study suggests that dietary n3 and n6 fatty acids intake might be inversely associated with the risk of hypertension in US adults. Further large-scale prospective studies and studies with more accurate dietary survey methods are required to confirm these findings.

[Image omitted. See PDF.]

[Image omitted. See PDF.]

[Image omitted. See PDF.]

	Non-Hypertension	Hypertension	p Value
Number of Participants (%)	9458 (51.3)	8976 (48.7)
Age group (%) 1			<0.01
18–39 years	5212 (55.1)	1245 (13.9)
40–59 years	2956 (31.3)	3026 (33.7)
60–79 years	1127 (11.9)	3783 (42.1)
≥80 years	163 (1.7)	922 (10.3)
Gender (%) 1			<0.01
Male	4403 (46.6)	4613 (51.4)
Female	5055 (53.4)	4363 (48.6)
Race (%) 1			<0.01
Mexican American	1670 (17.7)	1041 (11.6)
Other Hispanic	1083 (11.5)	767 (8.5)
Non-Hispanic White	4108 (43.4)	4254 (47.4)
Non-Hispanic Black	1584 (16.7)	2302 (25.6)
Other race	1013 (10.7)	612 (6.8)
Educational level (%) 1			<0.01
Below high school	2197 (23.2)	2435 (27.2)
High school	2061 (21.8)	2233 (24.9)
Above high school	5192 (54.9)	4299 (27.9)
Marital status (%) 1			0.706
Married/Living with partner	5141 (59.6)	5276 (59.4)
Widowed/Divorced/Separated/Never married	3478 (40.4)	3611 (40.6)
Household income (%) 1			<0.01
<$20,000	1770 (19.5)	2067 (23.9)
≥$20,000	7293 (80.5)	6570 (76.1)
Body mass index (%) 1			<0.01
<25 kg/m2	3660 (38.7)	1850 (20.7)
25 to <30 kg/m2	3113 (32.9)	2917 (32.6)
≥30 kg/m2	2677 (28.3)	4179 (46.7)
Work activity (%) 1			<0.01
Vigorous activity	1871 (19.8)	1470 (16.4)
Moderate activity	2118 (22.4)	1861 (20.7)
Other	5469 (57.8)	5645 (62.9)
Recreational activity (%) 1			<0.01
Vigorous activity	2815 (29.8)	1216 (13.5)
Moderate activity	2414 (25.5)	2524 (28.1)
Other	4229 (44.7)	5236 (58.3)
Smoking at least 100 cigarettes in life (%) 1	3663 (38.7)	4287 (47.8)	<0.01
Have at least 12 alcohol drinks/year (%) 1	6351 (67.1)	6013 (67.0)	0.818
Diabetes (%) 1	446 (4.7)	1757 (19.6)	<0.01
Total energy intake (kcal/day) 2	1977 (1043)	1837.5 (957.5)	<0.01
Total adjusted n3 fatty acid intake (mg/kg/day) 2	20.37 (16.05)	17.51 (13.92)	<0.01
Total adjusted n6 fatty acid intake (mg/kg/day) 2	189.16 (141.81)	159.24 (121.98)	<0.01
n6:n3 ratio 2	9.11 (3.17)	8.91 (3.05)	<0.01

Data are the number of subjects (percentage) or medians (interquartile ranges). 1 Chi-square test was used to compare the percentage between participants with and without hypertension. 2 Mann-Whitney U test was used to compare the mean values between participants with and without hypertension. National Health and Nutrition Examination Survey (NHANES).

	Case/Participants	Crude 1	Model 1 1	Model 2 1
Adjusted n3 (mg/Kg/day)
<14.65	3398/6138	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
14.65 to <24.32	3036/6158	0.79 (0.71–0.88) **	0.78 (0.68–0.90) **	0.78 (0.67–0.91) **
≥24.32	2542/6138	0.62 (0.56–0.69) **	0.58 (0.52–0.65) **	0.58 (0.49–0.68) **
Adjusted n6 (mg/Kg/day)
<135.78	3460/6138	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
135.78 to <221.11	3029/6158	0.75 (0.68–0.83) **	0.71 (0.62–0.80) **	0.70 (0.62–0.80) **
≥221.11	2487/6138	0.58 (0.53–0.64) **	0.58 (0.52–0.65) **	0.53 (0.45–0.63) **
n6:n3 ratio
<8.11	3143/6138	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.11 to <10.04	3023/6158	1.00 (0.91–1.10)	1.13 (1.01–1.26) *	1.10 (0.99–1.23)
≥10.04	2810/6138	0.82 (0.73–0.93) **	0.96 (0.84–1.09)	0.92 (0.80–1.06)

1 Calculated using binary logistic regression. Model 1 adjusted for age and gender. Model 2 adjusted for age and gender, race, educational level, income, recreational activity, work activity, drinking status, smoking status, diabetes, and total energy intake. * p <0.05; ** p <0.01.

	Male			Female
	Crude 1	Model 1 1	Model 1	Crude 1	Model 1 1	Model 2 1
Adjusted n3 (mg/Kg/day)
<14.65	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
14.65 to <24.32	0.74 (0.64–0.87) **	0.77 (0.64–0.93) **	0.77 (0.63–0.95) *	0.81 (0.69–0.96) *	0.78 (0.64–0.95) *	0.78 (0.63–0.97) *
≥24.32	0.60 (0.51–0.71) **	0.61 (0.51–0.73) **	0.61 (0.48–0.79) **	0.62 (0.53–0.72) **	0.54 (0.46–0.65) **	0.53 (0.41–0.68) **
Adjusted n6 (mg/Kg/day)
<135.78	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
135.78 to <221.11	0.66 (0.56–0.77) **	0.65 (0.54–0.78) **	0.63 (0.52–0.75) **	0.81 (0.68–0.96) *	0.76 (0.62–0.92) **	0.76 (0.61–0.96) *
≥221.11	0.53 (0.46–0.61) **	0.56 (0.47–0.66) **	0.49 (0.38–0.63) **	0.60 (0.51–0.70) **	0.59 (0.49–0.70) **	0.56 (0.43–0.72) **
n6:n3 ratio
<8.11	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.11 to <10.04	0.94 (0.81–1.08)	1.07 (0.91–1.25)	1.05 (0.90–1.24)	1.06 (0.91–1.23)	1.18 (0.98–1.42)	1.14 (0.95–1.38)
≥10.04	0.80 (0.68–0.95) *	0.90 (0.76–1.08)	0.87 (0.73–1.05)	0.83 (0.70–0.97) *	1.02 (0.84–1.24)	0.98 (0.81–1.20)

1 Calculated using binary logistic regression. Model 1 adjusted for age. Model 2 adjusted for age, race, educational level, income, recreational activity, work activity, drinking status, smoking status, diabetes, and total energy intake. * p < 0.05; ** p < 0.01.

	Hypertension			Stage 1 Hypertension			Stage 2 Hypertension
	Crude 1	Model 1 1	Model 2 1	Crude 2	Model 1 2	Model 2 2	Crude 2	Model 1 2	Model 2 2
Adjusted n3 (mg/Kg/day)
<15.46	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
15.46 to <25.58	0.82 (0.71–0.96) *	0.81 (0.69–0.96) *	0.76 (0.64–0.91) **	0.89 (0.80–1.01)	0.86 (0.77–0.97) *	0.82 (0.72–0.93) **	0.86 (0.74–0.99) *	0.86 (0.74–1.01)	0.82 (0.69–0.96) *
≥25.58	0.71 (0.62–0.80) **	0.67 (0.59–0.77) **	0.60 (0.50–0.73) **	0.73 (0.64–0.82) **	0.70 (0.62–0.80) **	0.63 (0.54–0.74) **	0.64 (0.55–0.75) **	0.66 (0.56–0.77) **	0.63 (0.51–0.77) **
Adjusted n6 (mg/Kg/day)
<144.81	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
144.81 to <233.31	0.79 (0.69–0.90) **	0.75 (0.65–0.86) **	0.69 (0.59–0.80) **	0.85 (0.75–0.95) **	0.82 (0.73–0.93) **	0.77 (0.68–0.88) **	0.69 (0.60–0.80) **	0.71 (0.61–0.83) **	0.66 (0.56–0.78) **
≥233.31	0.65 (0.57–0.73) **	0.63 (0.55–0.71) **	0.52 (0.43–0.62) **	0.70 (0.62–0.78) **	0.70 (0.62–0.79) **	0.57 (0.49–0.67) **	0.54 (0.46–0.63) **	0.62 (0.52–0.73) **	0.54 (0.44–0.67) **
n6:n3 ratio
<8.17	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.17 to <10.13	1.07 (0.93–1.23)	1.16 (1.00–1.35)	1.15 (0.99–1.33)	0.98 (0.87–1.10)	1.06 (0.94–1.19)	1.04 (0.92–1.18)	0.86 (0.75–1.00)	1.03 (0.88–1.21)	0.99 (0.84–1.17)
≥10.13	0.90 (0.77–1.06)	0.97 (0.81–1.14)	0.95 (0.79–1.14)	0.93 (0.83–1.05)	1.00 (0.89–1.14)	0.96 (0.85–1.09)	0.73 (0.63–0.85) **	0.91 (0.78–1.08)	0.85 (0.72–1.01)

1 Calculated using binary logistic regression. 2 Calculated using multinomial logistic regression. Model 1 adjusted for age and gender. Model 2 adjusted for age and gender, race, educational level, income, recreational activity, work activity, drinking status, smoking status, diabetes, and total energy intake. * p < 0.05; ** p < 0.01.

Author Contributions

J.C. and D.Z. conceived and designed the study; J.C. and B.S. analyzed the data; J.C. and D.Z. wrote the paper; D.Z. reviewed the manuscript and had primary responsibility for the final content. All authors provided critical revisions of the manuscript and approved the final manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global Burden of Hypertension: Analysis of Worldwide Data. Lancet 2005, 365, 217-223.

2. Zhang, Y.; Moran, A.E. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension among Young Adults in the United States, 1999 to 2014. Hypertension 2017, 70, 736-742.

3. Benjamin, E.J.; Blaha, M.J.; Chiuve, S.E.; Cushman, M.; Das, S.R.; Deo, R.; de Ferranti, S.D.; Floyd, J.; Fornage, M.; Gillespie, C.; et al. Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association. Circulation 2017, 135, 146-603.

4. Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; Amann, M.; Anderson, H.R.; Andrews, K.G.; Aryee, M.; et al. A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2224-2260.

5. Ninomiya, T. Risk of Stroke in Kidney Disease. Contrib. Nephrol. 2013, 179, 58-66.

6. Hisham, N.F.; Bayraktutan, U. Epidemiology, Pathophysiology, and Treatment of Hypertension in Ischaemic Stroke Patients. J. Stroke Cerebrovasc. Dis. 2013, 22, 4-14.

7. Faraco, G.; Iadecola, C. Hypertension: A Harbinger of Stroke and Dementia. Hypertension 2013, 62, 810-817.

8. Ljutic, D.; Kes, P. The Role of Arterial Hypertension in the Progression of Non-Diabetic Glomerular Diseases. Nephrol. Dial. Transplant. 2003, 18, 28-30.

9. Chen, J.; Zhang, C.; Wu, Y.; Zhang, D. Association between Hypertension and the Risk of Parkinson's Disease: A Meta-Analysis of Analytical Studies. Neuroepidemiology 2019, 52, 181-192.

10. Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr.; Collins, K.J.; Himmelfarb, C.D.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 Acc/Aha/Aapa/Abc/Acpm/Ags/Apha/Ash/Aspc/Nma/Pcna Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2018, 71, 127-248.

11. Wu, L.; Sun, D.; He, Y. Fruit and Vegetables Consumption and Incident Hypertension: Dose-Response Meta-Analysis of Prospective Cohort Studies. J. Hum. Hypertens. 2016, 30, 573-580.

12. Li, B.; Li, F.; Wang, L.; Zhang, D. Fruit and Vegetables Consumption and Risk of Hypertension: A Meta-Analysis. J. Clin. Hypertens. (Greenwich) 2016, 18, 468-476.

13. Borgi, L.; Muraki, I.; Satija, A.; Willett, W.C.; Rimm, E.B.; Forman, J.P. Fruit and Vegetable Consumption and the Incidence of Hypertension in Three Prospective Cohort Studies. Hypertension 2016, 67, 288-293.

14. Lelong, H.; Blacher, J.; Baudry, J.; Adriouch, S.; Galan, P.; Fezeu, L.; Hercberg, S.; Kesse-Guyot, E. Individual and Combined Effects of Dietary Factors on Risk of Incident Hypertension: Prospective Analysis from the Nutrinet-Sante Cohort. Hypertension 2017, 70, 712-720.

15. Sun, B.; Shi, X.; Wang, T.; Zhang, D. Exploration of the Association between Dietary Fiber Intake and Hypertension among U.S. Adults Using 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: Nhanes 2007(-)2014. Nutrients 2018, 10, 1091.

16. Yao, J.; Hu, P.; Zhang, D. Associations between Copper and Zinc and Risk of Hypertension in Us Adults. Biol. Trace Elem. Res. 2018, 186, 346-353.

17. Nakamura, H.; Hara, A.; Tsujiguchi, H.; Nguyen, T.T.T. Relationship between Dietary N-6 Fatty Acid Intake and Hypertension: Effect of Glycated Hemoglobin Levels. Nutrients 2018, 10, 1825.

18. Kambayashi, Y.; Miyagi, S.; Yamada, Y.; Suzuki, K.; Shimizu, Y.; Nakamura, H.; Colussi, G.; Catena, C.; Novello, M.; Bertin, N.; et al. Impact of Omega-3 Polyunsaturated Fatty Acids on Vascular Function and Blood Pressure: Relevance for Cardiovascular Outcomes. Nutrients 2017, 27, 191-200.

19. Cao, Y.; Lu, L.; Liang, J.; Liu, M.; Li, X.; Sun, R.; Zheng, Y.; Zhang, P. Omega-3 Fatty Acids and Primary and Secondary Prevention of Cardiovascular Disease. Cell Biochem. Biophys. 2015, 72, 77-81.

20. Lorente-Cebrian, S.; Costa, A.G.; Navas-Carretero, S.; Zabala, M.; Martinez, J.A.; Moreno-Aliaga, M.J. Role of Omega-3 Fatty Acids in Obesity, Metabolic Syndrome, and Cardiovascular Diseases: A Review of the Evidence. J. Physiol. Biochem. 2013, 69, 633-651.

21. Maki, K.C.; Dicklin, M.R. Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut? Nutrients 2018, 10, 864.

22. Elagizi, A.; Lavie, C.J.; Marshall, K.; DiNicolantonio, J.J.; O'Keefe, J.H.; Milani, R.V. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review. Prog. Cardiovasc Dis. 2018, 61, 76-85.

23. Tortosa-Caparros, E.; Navas-Carrillo, D.; Marin, F.; Orenes-Pinero, E. Anti-Inflammatory Effects of Omega 3 and Omega 6 Polyunsaturated Fatty Acids in Cardiovascular Disease and Metabolic Syndrome. Crit. Rev. Food Sci. Nutr. 2017, 57, 3421-3429.

24. Delgado, G.E.; Marz, W.; Lorkowski, S.; von Schacky, C.; Kleber, M.E. Omega-6 Fatty Acids: Opposing Associations with Risk-the Ludwigshafen Risk and Cardiovascular Health Study. J. Clin. Lipidol. 2017, 11, 1082-1090.

25. Balk, E.M.; Lichtenstein, A.H. Omega-3 Fatty Acids and Cardiovascular Disease: Summary of the 2016 Agency of Healthcare Research and Quality Evidence Review. Nutrients 2017, 9, 865.

26. Simopoulos, A.P. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients 2016, 8, 128.

27. Martinez-Fernandez, L.; Laiglesia, L.M.; Huerta, A.E.; Martinez, J.A.; Moreno-Aliaga, M.J. Omega-3 Fatty Acids and Adipose Tissue Function in Obesity and Metabolic Syndrome. Prostaglandins Lipid Mediat. 2015, 121, 24-41.

28. Albracht-Schulte, K.; Kalupahana, N.S.; Ramalingam, L.; Wang, S.; Rahman, S.M.; Robert-McComb, J.; Moustaid-Moussa, N. Omega-3 Fatty Acids in Obesity and Metabolic Syndrome: A Mechanistic Update. Psychopharmacology (Berl) 2018, 58, 1-16.

29. Yary, T.; Voutilainen, S.; Tuomainen, T.P.; Ruusunen, A.; Nurmi, T.; Virtanen, J.K. Omega-6 Polyunsaturated Fatty Acids, Serum Zinc, Delta-5-and Delta-6-Desaturase Activities and Incident Metabolic Syndrome. J. Hum. Nutr. Diet. 2017, 30, 506-514.

30. Brayner, B.; Kaur, G.; Keske, M.A.; Livingstone, K.M. Fads Polymorphism, Omega-3 Fatty Acids and Diabetes Risk: A Systematic Review. Nutrients 2018, 10, 758.

31. Jamilian, M.; Samimi, M.; Ebrahimi, F.A.; Hashemi, T.; Taghizadeh, M.; Razavi, M.; Sanami, M.; Asemi, Z. The Effects of Vitamin D and Omega-3 Fatty Acid Co-Supplementation on Glycemic Control and Lipid Concentrations in Patients with Gestational Diabetes. Nutrients 2017, 11, 459-468.

32. Chen, C.; Yang, Y.; Yu, X.; Hu, S.; Shao, S. Association between Omega-3 Fatty Acids Consumption and the Risk of Type 2 Diabetes: A Meta-Analysis of Cohort Studies. J. Diabetes Investig. 2017, 8, 480-488.

33. Thota, R.N.; Acharya, S.H.; Abbott, K.A.; Garg, M.L. Curcumin and Long-Chain Omega-3 Polyunsaturated Fatty Acids for Prevention of Type 2 Diabetes (Cop-D): Study Protocol for a Randomised Controlled Trial. Trials 2016, 17, 565.

34. Strom, M.; Halldorsson, T.I.; Mortensen, E.L.; Torp-Pedersen, C.; Olsen, S.F. Fish, N-3 Fatty Acids, and Cardiovascular Diseases in Women of Reproductive Age: A Prospective Study in a Large National Cohort. Hypertension 2012, 59, 36-43.

35. Levinson, P.D.; Iosiphidis, A.H.; Saritelli, A.L.; Herbert, P.N.; Steiner, M. Effects of N-3 Fatty Acids in Essential Hypertension. Am. J. Hypertens. 1990, 3, 754-760.

36. Knapp, H.R.; FitzGerald, G.A. The Antihypertensive Effects of Fish Oil. A Controlled Study of Polyunsaturated Fatty Acid Supplements in Essential Hypertension. N. Engl. J. Med. 1989, 320, 1037-1043.

37. Mirmiran, P.; Hosseinpour-Niazi, S.; Naderi, Z.; Bahadoran, Z.; Sadeghi, M.; Azizi, F. Association between Interaction and Ratio of Omega-3 and Omega-6 Polyunsaturated Fatty Acid and the Metabolic Syndrome in Adults. Nutrition 2012, 28, 856-863.

38. Wang, L.; Manson, J.E.; Forman, J.P.; Gaziano, J.M.; Buring, J.E.; Sesso, H.D. Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women. Hypertension 2010, 56, 598-604.

39. Djousse, L.; Arnett, D.K.; Pankow, J.S.; Hopkins, P.N.; Province, M.A.; Ellison, R.C. Dietary Linolenic Acid Is Associated with a Lower Prevalence of Hypertension in the Nhlbi Family Heart Study. Hypertension 2005, 45, 368-373.

40. Centers for Disease, Control, and Prevention. Physician Examination Procedures Manual. Available online: https://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/PE.Pdf (accessed on 26 July 2018).

41. Naqvi, A.Z.; Davis, R.B.; Mukamal, K.J. Dietary Fatty Acids and Peripheral Artery Disease in Adults. Atherosclerosis 2012, 222, 545-550.

42. U.S. Department of Agriculture, Agricultural Research Service. Usda Food and Nutrient Database for Dietary Studies. Available online: https://Www.Cdc.Gov/Nchs/Tutorials/Dietary/Surveyorientation/ Resourcedietaryanalysis/Intro.Htm (accessed on 26 July 2018).

43. Ueshima, H.; Stamler, J.; Elliott, P.; Chan, Q.; Brown, I.J.; Carnethon, M.R.; Daviglus, M.L.; He, K.; Moag-Stahlberg, A.; Rodriguez, B.L.; et al. Food Omega-3 Fatty Acid Intake of Individuals (Total, Linolenic Acid, Long-Chain) and Their Blood Pressure: Intermap Study. Hypertension 2007, 50, 313-319.

44. Appel, L.J.; Miller, E.R., 3rd; Seidler, A.J.; Whelton, P.K. Does Supplementation of Diet with 'Fish Oil' Reduce Blood Pressure? A Meta-Analysis of Controlled Clinical Trials. Arch. Intern. Med. 1993, 153, 1429-1438.

45. Skilton, M.R.; Raitakari, O.T.; Celermajer, D.S. High Intake of Dietary Long-Chain Omega-3 Fatty Acids Is Associated with Lower Blood Pressure in Children Born with Low Birth Weight: Nhanes 2003-2008. Hypertension 2013, 61, 972-976.

46. Nestel, P.; Shige, H.; Pomeroy, S.; Cehun, M.; Abbey, M.; Raederstorff, D. The N-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid Increase Systemic Arterial Compliance in Humans. Am. J. Clin. Nutr. 2002, 76, 326-330.

47. Knapp, H.R. Dietary Fatty Acids in Human Thrombosis and Hemostasis. Am. J. Clin. Nutr. 1997, 65, 1687-1698.

48. Mori, T.A. Effect of Fish and Fish Oil-Derived Omega-3 Fatty Acids on Lipid Oxidation. Redox Rep. 2004, 9, 193-197.

49. Hoffmann, P.; Block, H.U.; Beitz, J.; Taube, C.; Forster, W.; Wortha, P.; Singer, P.; Naumann, E.; Heine, H. Comparative Study of the Blood Pressure Effects of Four Different Vegetable Fats on Young, Spontaneously Hypertensive Rats. Lipids 1986, 21, 733-737.

50. Rupp, H.; Turcani, M.; Ohkubo, T.; Maisch, B.; Brilla, C.G. Dietary Linolenic Acid-Mediated Increase in Vascular Prostacyclin Formation. Mol. Cell. Biochem. 1996, 162, 59-64.

51. Petersson, H.; Basu, S.; Cederholm, T.; Riserus, U. Serum Fatty Acid Composition and Indices of Stearoyl-Coa Desaturase Activity Are Associated with Systemic Inflammation: Longitudinal Analyses in Middle-Aged Men. Br. J. Nutr. 2008, 99, 1186-1189.

52. Petersson, H.; Lind, L.; Hulthe, J.; Elmgren, A.; Cederholm, T.; Riserus, U. Relationships between Serum Fatty Acid Composition and Multiple Markers of Inflammation and Endothelial Function in an Elderly Population. Atherosclerosis 2009, 203, 298-303.

53. Shimokawa, H.; Vanhoutte, P.M. Dietary Omega 3 Fatty Acids and Endothelium-Dependent Relaxations in Porcine Coronary Arteries. Am. J. Physiol. 1989, 256, 968-973.

54. Chu, Z.M.; Yin, K.; Beilin, L.J. Fish Oil Feeding Selectively Attenuates Contractile Responses to Noradrenaline and Electrical Stimulation in the Perfused Mesenteric Resistance Vessels of Spontaneously Hypertensive Rats. Clin. Exp. Pharmacol. Physiol. 1992, 19, 177-181.

55. Fischer, R.; Dechend, R.; Qadri, F.; Markovic, M.; Feldt, S.; Herse, F.; Park, J.K.; Gapelyuk, A.; Schwarz, I.; Zacharzowsky, U.B.; et al. Dietary N-3 Polyunsaturated Fatty Acids and Direct Renin Inhibition Improve Electrical Remodeling in a Model of High Human Renin Hypertension. Hypertension 2008, 51, 540-546.

56. Echeverria, F.; Ortiz, M.; Valenzuela, R.; Videla, L.A. Long-Chain Polyunsaturated Fatty Acids Regulation of Ppars, Signaling: Relationship to Tissue Development and Aging. Prostaglandins Leukot. Essent. Fatty Acids 2016, 114, 28-34.

57. Lasztity, N.; Hamvas, J.; Biro, L.; Nemeth, E.; Marosvolgyi, T.; Decsi, T.; Pap, A.; Antal, M. Effect of Enterally Administered N-3 Polyunsaturated Fatty Acids in Acute Pancreatitis-A Prospective Randomized Clinical Trial. Clin. Nutr. 2005, 24, 198-205.

58. Huang, T.; Wahlqvist, M.L.; Li, D. Docosahexaenoic Acid Decreases Plasma Homocysteine Via Regulating Enzyme Activity and Mrna Expression Involved in Methionine Metabolism. Nutrition 2010, 26, 112-119.

59. Vessby, B. Dietary Fat, Fatty Acid Composition in Plasma and the Metabolic Syndrome. Curr. Opin. Lipidol. 2003, 14, 15-19.